Daver, Naval G.
Iqbal, Shahed
Renard, Camille
Chan, Rebecca J.
Hasegawa, Ken
Hu, Hao
Tse, Preston
Yan, Jiajun
Zoratti, Michael J.
Xie, Feng
Ramsingh, Giridharan
Funding for this research was provided by:
Gilead Sciences, Inc.
Article History
Received: 15 November 2022
Accepted: 26 February 2023
First Online: 6 March 2023
Declarations
:
: Not applicable.
: Not applicable.
: SI, RC, CR, KH, and GR are employees and stockholders of Gilead Sciences, Inc. CR is an Alphabet stockholder. NGD has received grants or contracts from Hanmi, Trovagene, Fate Therapeutics, Novimmune, and GlycoMimetics; consulting fees from Arog, Novartis, Jazz, Celgene, Syndax, Shattuck Labs, and Agios; and grants or contracts and consulting fees from Daiichi-Sankyo, Bristol-Meyers Squibb, Pfizer, Gilead Sciences, Inc., Servier, Genentech, Astellas, AbbVie, ImmunoGen, Amgen, and Trillium. HH, JY, PT, MJZ, and FX have nothing to disclose.